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Objectives The aim of this study was to examine the incidence, correlates, and consequences of
intra-procedural stent thrombosis (IPST) in patients with acute coronary syndromes (ACS).
Background Stent thrombosis (ST) is a rare but serious complication of percutaneous coronary interven-
tion (PCI). The Academic Research Consortium deﬁnition of ST excludes events occurring during PCI.
Methods Angiograms from the ACUITY (Acute Catheterization and Urgent Intervention Triage
StrategY) and HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute
Myocardial Infarction) trials were reviewed frame-by-frame at an independent core laboratory for the
occurrence of IPST. Patients with versus without IPST were compared to identify baseline character-
istics associated with IPST and demonstrate the independent association between IPST and adjudi-
cated events at 30 days and 1 year.
Results Intra-procedural ST occurred in 47 (0.7%) of 6,591 patients. The occurrence of IPST was associ-
ated with ST-segment elevation myocardial infarction presentation, high white blood cell count, treat-
ment of thrombotic and bifurcation lesions, bivalirudin monotherapy, bail-out IIb/IIIa inhibitor use, and
implantation of bare-metal (rather than drug-eluting) stents. Major adverse ischemic events were mark-
edly higher in patients with versus without IPST, including mortality at 30 days (12.9% vs. 1.4%, p 
0.0001) and 1 year (12.9% vs. 3.1%, p  0.0001). Out-of-lab Academic Research Consortium deﬁnite or
probable ST also occurred signiﬁcantly more often among IPST patients at 30 days (17.4% vs. 1.8%, p 
0.0001) and 1 year (19.9% vs. 2.7%, p  0.0001). Intra-procedural ST was a signiﬁcant independent pre-
dictor of 1-year mortality (hazard ratio: 3.86, 95% conﬁdence interval: 1.66 to 9.00, p  0.002).
Conclusions Intra-procedural ST is a relatively rare complication of PCI in ACS but is strongly asso-
ciated with subsequent out-of-lab ST and mortality. Intra-procedural ST should be considered as a
distinct category of ST and routinely reported, particularly for ACS patients. (J Am Coll Cardiol Intv
2013;6:36–43) © 2013 by the American College of Cardiology Foundation
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37Stent thrombosis (ST) occurring after percutaneous coro-
nary intervention (PCI) is a rare but serious complication.
The incidence of ST is known to be increased in patients
undergoing PCI in the setting of an acute coronary syn-
drome (ACS) and in those with diabetes mellitus or
bifurcation stents and in patients who discontinue dual
antiplatelet therapy (1–3).
The Academic Research Consortium (ARC) has stan-
dardized the definitions of ST by categorizing the specificity
of the adjudicated event (definite, probable, or possible) and
its timing relative to PCI (acute, subacute, late, and very
late) (4). However, all of these categories refer to events
occurring after the patient has left the cardiac catheteriza-
tion laboratory. Intra-procedural stent thrombosis (IPST)
(i.e., the development of occlusive or non-occlusive new
thrombus in or adjacent to a recently implanted stent before
the PCI procedure is completed) is excluded from the ARC
ST definitions. As such, little is known about the incidence,
predictors, and consequences of IPST.
With 2 recently performed large-scale trials of PCI in
ACS (the HORIZONS-AMI [Harmonizing Outcomes
with RevascularIZatiON and Stents in Acute Myocardial
Infarction] and ACUITY [Acute Catheterization and Ur-
gent Intervention Triage StrategY] trials)—in which inde-
pendent adjudication of intra-procedural angiographic
events in addition to early and late clinical events were
performed—we sought to examine the frequency, correlates,
and implications of IPST.
Methods
The HORIZONS-AMI and ACUITY protocols and prin-
cipal results have been described in detail. In brief, in the
HORIZONS-AMI trial 3,602 patients presenting with
ST-segment elevation myocardial infarction (STEMI)
within 12 h of symptom onset were randomized before
angiography to bivalirudin or heparin plus a glycoprotein
IIb/IIIa inhibitor (GPI) (1:1 ratio) (5). Subsequently, 3,006
patients suitable for stenting were randomized again to a
paclitaxel-eluting stent or to an identical bare-metal stent
(3:1 ratio). In the ACUITY trial 13,819 patients with
moderate and high-risk unstable angina and non-STEMI
were randomized to 1 of 3 antithrombotic regimens: hepa-
rin plus GPI, bivalirudin plus GPI, or bivalirudin alone (6).
Angiography was performed in all patients within 72 h,
followed by triage to PCI, coronary artery bypass graft
(CABG) surgery, or medical therapy at the discretion of the
treating physician. All patients in both trials received
standard pharmacological therapy to support PCI, including
routine dual antiplatelet therapy with aspirin and clopi-
dogrel for at least 1 year. Clinical follow-up was performed
through 3 years in the HORIZONS-AMI trial and through
1 year in the ACUITY trial. tFrame-by-frame angiographic analysis was performed at an
independent angiographic core laboratory (Cardiovascular Re-
search Foundation, New York, New York) by trained techni-
cians blinded to randomization and clinical events with stan-
dard definitions for lesion morphology, thrombus, and
Thrombolysis In Myocardial Infarction (TIMI) flow grades
(7–9). Each film was analyzed independently by 2 separate
technicians: 1 reader (blinded to intra-procedural events) as-
sessed only the baseline (pre-PCI) images and the final result,
whereas a second reader assessed intra-procedural events. All
films were over-read for accuracy by the laboratory director or
co-director, who were also blinded to randomization and
clinical events and have extensive
experience in interventional pro-
cedures. Core laboratory analysis
was performed in all patients in
the HORIZONS-AMI trial and
in U.S. patients in the ACUITY
trial as part of a formal substudy.
The complete HORIZONS-
AMI and ACUITY databases
were merged, and the present
analysis was restricted to patients
who underwent PCI and in
whom angiographic core labora-
tory evaluation of the index pro-
cedure was performed.
Intra-procedural ST was de-
fined as new or increasing (com-
pared with baseline) thrombus
within or adjacent to a deployed
stent occurring during the index
PCI procedure, whether occlusive
or nonocclusive. Intra-procedural
ST was also deemed present when
the baseline level of thrombus was
decreasing or resolved after bal-
loon angioplasty or thrombus as-
piration but then increased any
time after stent implantation (in-
cluding stent post-dilation). Clin-
ical events in each trial—including
death, myocardial infarction (MI), target vessel revasculariza-
tion, and ST according to the ARC definitions—were assessed
at 30 days and 1 year in both studies by an independent clinical
events committee with original source documents, blinded to
randomized allocation of treatment.
Continuous variables are presented as median with inter-
quartile range and were compared with the Kruskal-Wallis
test. Categorical variables are presented as proportions and
were compared with chi-square or Fischer exact test. A
multivariable stepwise Cox regression model (entry and exit
p  0.1) was developed to identify the independent predic-
Abbreviations
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38variables considered in the model (on the basis of common
predictive variables from the respective models from the
ACUITY [10] and HORIZONS-AMI [11] trials) were
ge, sex, baseline hemoglobin, baseline white blood cell
ount, current smoking, prior PCI, use of aspirin or thien-
pyridines at any time before ACS, number of diseased
essels, baseline TIMI flow grade 0/1, bivalirudin alloca-
ion, thrombus at baseline, final (post-PCI) TIMI flow
rade (0 to 2 vs. 3), and IPST. Significance level was set at
.05. All analyses were performed with SAS (version 9.0;
AS Institute, Cary, North Carolina).
esults
Percutaneous coronary intervention was performed in 6,591
patients in the combined cohort, including 3,428 patients
with unstable angina or non-STEMI from the ACUITY
trial and 3,173 patients with STEMI from the
HORIZONS-AMI trial. Intra-procedural ST occurred in
47 patients (0.7%), in 49 lesions. These included 37 patients
from the HORIZONS-AMI trial (1.2%) and 10 patients
from the ACUITY trial (0.3%), p  0.001. Examples of
PST are shown in Figure 1.
Figure 1. Examples of Intra-Procedural Stent ThrombosisTwo examples of intra-procedural stent thrombosis with resolution (A) and persistenThe baseline clinical and angiographic characteristics of
patients in whom IPST did and did not develop are shown
in Table 1. Patients with IPST were more likely to have
STEMI presentation, higher white blood cell count on
admission, randomization to bivalirudin alone, subse-
quent bail-out use of GPI, 1-vessel coronary artery
disease, an occluded artery at baseline with thrombus,
bifurcation lesions, and bare-metal stents implanted. The
peak intra-procedural activated clotting time (ACT) was
not significantly different between patients with versus
without IPST (342  117 s vs. 310  114 s, respectively,
p  0.09).
During PCI, certain intra-procedural complications were
significantly more common in the IPST group: slow or no
reflow 75.5% versus 3.2%, p  0.0001; distal embolization
49% versus 1.9%, p  0.0001; and side branch closure
14.3% versus 0.6%, p 0.0001. At the end of the index PCI,
IMI flow grade 3 in the treated vessel was present in 21
atients (44.7%) in the IPST group, compared with 6,014
atients (90.9%) in the no IPST group (p 0.0001). Residual
hrombus was present within or adjacent to the stent in 31.9%
f patients (15 of 47) in the IPST group versus 1.0% (62 of
,515) in the no IPST group (p  0.0001). Median peak
reatine kinase-myocardial band was significantly higher in thece (B).
bphenou
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39IPST group: 18.3 (4.4 to 38.9) ng/ml versus 7.6 (2.4 to 24.0)
ng/ml, respectively (p  0.02).
As shown in Tables 2 and 3 and Figure 2, adverse events
at 30-day and 1-year follow-up were markedly higher in
patients with compared with those without IPST. Of note,
the out-of-lab rates of ST according to the ARC definitions
(recurrent clinical ST events among patient undergoing
IPST) were also greatly increased in patients with IPST
(Fig. 3), with most of these being angiographically proven
definite ST events, and with most occurring by 30 days.
Table 1. Baseline Clinical and Angiographic Characte
Variable IPST
Age 61.4 [5
Male 74.
Diabetes mellitus 17.
Insulin-treated 10.
Current cigarette smoker 34.
Hypertension 57.
Hyperlipidemia 47.
Previous MI 14.
Previous PCI 17.
Previous CABG 6.
Clinical presentation
Unstable angina 4.
Non-STEMI 17.
STEMI 78.
Baseline creatinine clearance, ml/min 86 [6
Baseline hemoglobin (g/dl) 14.3 [1
Baseline white blood cell count (103) 10.7 [8
Baseline platelet count (103) 235 [2
Randomized treatment: bivalirudin alone 59.
GPI used for bailout 64.
Number of diseased vessels
1 76.
2 8.
3 14.
Baseline TIMI 0/1 ﬂow 74.
Number of vessels treated 1 [1
Number of lesions treated 2 [2
Any LM lesion intervened
Any LAD lesion intervened 38.
Any LCX lesion intervened 21.
Any RCA lesion intervened 38.
Any SVG lesion intervened 4.
Any lesion with thrombus treated 87.
Any bifurcation lesion treated 51.
Any stent used 10
Any drug-eluting stent used 66.
Only bare-metal stents used 3
Values are mean (range) or % (n/N).
CABG  coronary artery bypass grafting; GPI  glycoprotein IIb/I
descending; LCX  left circumflex; LM  left main; MI  myocardial
artery; STEMI ST-segment elevationmyocardial infarction; SVG saAdverse ischemic, hemorrhagic, and out-of-lab ST events Cwere increased even among patients in whom final TIMI
flow grade 3 was restored (Table 3).
By multivariable analysis, the occurrence of IPST was
an independent predictor of 1-year all-cause mortality
(hazard ratio [HR]: 3.86, 95% confidence interval [CI]:
1.66 to 9.00, p  0.002). Other independent predictors
of mortality were diabetes mellitus (HR: 1.99, 95% CI:
1.46 to 2.73, p  0.0001), final TIMI flow grade 0 to 2
(HR: 0.29, 95% CI: 2.33 to 5.00, p  0.0001), and
aseline creatinine clearance (per ml/min, HR: 0.97, 95%
s of Patients With and Without IPST
7) No IPST (n  6,544) p Value
.5] 60.6 [52.7–70.0] 0.91
/47) 73.5% (4,812/6,544) 1.0
7) 24.2% (1,581/6,528) 0.31
0) 10.5% (440/4,182) 1.0
/47) 39.1% (2,555/6,531) 0.55
/47) 61.1% (3,990/6,529) 0.65
/46) 52.5% (3,416/6,501) 0.56
7) 22.7% (1,463/6,452) 0.29
7) 29.3% (1,913/6,525) 0.08
7) 12.6% (821/6,535) 0.27
7) 24.3% (1,587/6,544) 0.0005
7) 28.0% (1,831/6,544) 0.10
/47) 47.8% (3,126/6,544) 0.0001
] 90 [69–116] 0.20
.7] 14.3 [13.2–15.3] 0.58
20] 9.20 [7.2–11.8] 0.002
3] 236 [197–281] 0.66
/47) 41.3% (2,701/6,544) 0.02
/28) 10.8% (292/2,697) 0.0001
/47) 54.7% (3,580/6,541) 0.003
7) 20.4% (1,335/6,541) 0.04
7) 24.5% (1,603/6,541) 0.17
/47) 37.7% (2,462/6,523) 0.0001
1 [1,1] 0.10
2 [2–3] 0.69
7) 0.2% (10/4,105) 1.0
/47) 41.1% (2,685/6,540) 0.77
/47) 26.5% (1,730/6,530) 0.51
/47) 41.5% (2,713/6,540) 0.77
7) 1.5% (96/6,540) 0.15
/47) 47.1% (3,074/6,529) 0.0001
/47) 28.2% (1,156/4,094) 0.001
/47) 99.8% (6,531/6,544) 1.0
/47) 80.9% (5,296/6,544) 0.015
/47) 19.1% (1,248/6,544) 0.015
itor; IPST  intra-procedural stent thrombosis; LAD  left anterior
n; PCI  percutaneous coronary intervention; RCA  right coronary
s vein graft; TIMI Thrombolysis In Myocardial Infarction flow grade.ristic
(n  4
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40Discussion
The present study is the largest reported experience with
IPST to date, the first to employ an independent angio-
graphic core laboratory to assess frame-by-frame events, and
the first to correlate IPST with early and late clinical
outcomes. The most important observations from this
report are: 1) IPST was a rare complication of PCI in ACS,
occurring in 1% of patients, even in those presenting with
TEMI; 2) IPST was not related to most baseline clinical
haracteristics, except for STEMI presentation and high
hite blood cell count, but occurred more frequently in
atients with angiographic evidence of thrombus before
CI, in those not treated with a GPI, with bare-metal stent
se, and in those undergoing bifurcation stenting; 3) al-
hough uncommon, IPST was a strong predictor of subop-
imal PCI results. Despite high use of bail-out GPI, TIMI
ow grade 3 was restored in less than one-half of patients in
hom IPST developed, and residual thrombus was present
Table 2. Clinical Events Through 30-Day and 1-Year Follow-Up
IPST
(n  47)
No IPST
(n  6,544)
Hazard Ratio
[95% CI] p Value
30-day events
Death 12.9% (6) 1.4% (87) 10.39 [4.54–23.77] 0.0001
MI 14.9% (7) 4.9% (313) 3.55 [1.68–7.52] 0.0004
Death or MI 28.0% (13) 5.9% (380) 5.49 [3.16–9.54] 0.0001
ST, deﬁnite or
probable
(ARC)
17.4% (8) 1.8% (117) 10.99 [5.37–22.51] 0.0001
Deﬁnite 15.3% (7) 1.3% (85) 12.94 [5.99–27.98] 0.0001
Probable 2.1% (1) 0.5% (32) 4.84 [0.66–35.46] 0.09
TVR 15.1% (7) 2.2% (141) 8.09 [3.79–17.29] 0.0001
Death, MI, or TVR 34.6% (16) 6.8% (435) 6.18 [3.75–10.18] 0.0001
TIMI major
bleeding
(non-CABG)
15.4% (7) 2.0% (131) 7.95 [3.72–17.01] 0.0001
Death, MI, TVR, or
TIMI major
bleeding
(non-CABG)
43.1% (20) 11.7% (755) 4.49 [2.88–7.00] 0.0001
1-yr events
Death 12.9% (6) 3.1% (200) 4.67 [2.07–10.52] 0.0001
MI 17.6% (8) 7.5% (472) 2.84 [1.41–5.70] 0.002
Death or MI 30.1% (14) 9.9% (627) 3.79 [2.23–6.44] 0.0001
ST, deﬁnite or
probable
(ARC)
19.9% (9) 2.7% (165) 9.19 [4.70–17.98] 0.0001
Deﬁnite 17.9% (8) 2.0% (127) 10.51 [5.14–21.48] 0.0001
Probable 2.1% (1) 0.7% (38) 4.12 [0.57–30.04] 0.13
TVR 22.8% (10) 7.9% (483) 3.79 [2.03–7.09] 0.0001
Death, MI, or TVR 41.1% (19) 14.5% (912) 3.93 [2.50–6.19] 0.0001
Values are % (n).
ARCAcademic ResearchConsortium; CI confidence interval; ST stent thrombosis; TVR
target vessel revascularization; other abbreviations as in Table 1.n more than 1 in 3 patients at procedure end; and 4) IPSTwas associated with a markedly higher incidence of mortal-
ity and other ischemic events within 30 days and 1 year after
the procedure, including ARC out-of-lab ST events, even if
final TIMI flow grade 3 was restored.
The impact of IPST has been evaluated in 2 prior studies.
Biondi-Zoccai et al. (12) reviewed the incidence of IPST in
patients undergoing PCI with first-generation drug-eluting
stents in Italy. Among 1,320 patients 75 years of age and
without cardiogenic shock (55% of whom had ACS), IPST
developed in 6 patients (0.5%), a rate similar to our study.
Total stent length and lack of GPI treatment were related to
IPST, but long-term follow-up was not reported from this
study. Similarly, Chieffo et al. (13) evaluated 670 patients
undergoing elective drug-eluting stent implantation and
documented IPST in 0.7%. Of the 5 patients, 1 had
complete resolution of the thrombus, 2 experienced non–
Q-wave MI, 1 had Q-wave MI, and 1 died while under-
going emergency surgical revascularization. Total stent
length was the only variable associated with IPST. In this
regard total stent length was not recorded in the ACUITY
Table 3. Clinical Events Through 30-Day and 1-Year Follow-Up in Patients
With Final TIMI Flow Grade 3
IPST
(n  21)
No IPST
(n  6,014)
Hazard Ratio
[95% CI] p Value
30-day events
Death 4.8% (1) 1.1% (64) 4.80 [0.67–34.62] 0.09
MI 14.3% (3) 4.8% (285) 3.41 [1.09–10.65] 0.02
Death or MI 19.0% (4) 5.6% (333) 3.91 [1.46–10.47] 0.003
ST, deﬁnite or
probable
(ARC)
14.3% (3) 1.7% (101) 9.69 [3.07–30.54] 0.0001
Deﬁnite 14.3% (3) 1.3% (77) 12.49 [3.94–39.59] 0.0001
Probable 0% (0) 0.4% (24) 4.84 [0.66–35.46] 0.78
TVR 19.6% (4) 2.2% (125) 10.81 [3.99–29.27] 0.0001
Death, MI, or TVR 29.3% (6) 6.5% (381) 5.40 [2.41–12.10] 0.0001
TIMI major
bleeding
(non-CABG)
10.1% (2) 1.9% (113) 5.28 [1.31–21.35] 0.009
Death, MI, TVR, or
TIMI major
bleeding
(non-CABG)
44.1% (9) 11.1% (658) 4.84 [2.51–9.35] 0.0001
1-yr events
Death 4.8% (1) 2.7% (161) 1.95 [0.27–13.90] 0.50
MI 14.3% (3) 7.4% (429) 2.34 [0.75–7.29] 0.13
Death or MI 19.0% (4) 9.5% (554) 2.44 [0.91–6.53] 0.07
ST, deﬁnite or
probable
(ARC)
14.3% (3) 2.5% (143) 7.03 [2.24–22.05] 0.0001
Deﬁnite 14.3% (3) 1.9% (114) 8.70 [2.77–27.39] 0.0001
Probable 0% (0) 0.6% (29) 4.12 [0.57–30.04] 0.76
TVR 19.3% (4) 8.0% (446) 3.20 [1.20–8.57] 0.01
Death, MI, or TVR 28.9% (6) 14.2% (820) 2.73 [1.22–6.09] 0.01
Values are % (n).Abbreviations as in Table 2.
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41trial, but the number of stents placed was higher in patients
with IPST in our analysis. Whether the association between
stent length and IPST reflects the need for additional stents
after IPST develops, represents the presence of more exten-
sive “vulnerable” atherosclerosis, or is truly causal cannot be
determined with certainty from our study.
In our study, the maximal ACT level did not significantly
differ between the groups with and without IPST, but it is
possible that additional doses of heparin were given in
response to IPST, elevating a previously low ACT. Of note,
although bivalirudin typically results in a higher ACT level
than heparin (with or without GPI), anticoagulation with
bivalirudin alone was associated with an increased incidence
of ST compared with unfractionated heparin, enoxaparin, or
bivalirudin plus a GPI. This observation is consistent with
our previous report of a higher rate of acute ST occurring
within the first 4 to 5 h in STEMI patients treated with
bivalirudin alone (14). Nonetheless, treatment of patients
with STEMI with bivalirudin alone resulted in reduced
30-day and 3-year mortality compared with heparin plus a
GPI, with comparable rates of ST at 3 years (14,15). Of
note, ST is a platelet-mediated event (16), and neither
prasugrel nor ticagrelor (which are known to reduce early
and late ST compared with clopidogrel (17,18) were avail-
able during the enrollment periods of the ACUITY and
HORIZONS-AMI trials. Thus, future studies are war-
Figure 2. Major Adverse Ischemic Events During 1-Year Follow-Up in Patie
Major adverse ischemic events during 1-year follow-up in patients in whom in
interval; HR  hazard ratio; MI  myocardial infarction; TVR  target vessel reranted to determine whether combining a more potentadenosine diphosphate antagonist with bivalirudin might
reduce IPST as well as acute ST and thereby further
improve outcomes in patients with ACS.
The present study does not address the cause of IPST,
and with only 47 patients with IPST events, robust multi-
variable analysis to identify the independent predictors of
IPST was not possible. Procedural complications such as
IPST can occur because of a variety of causes, such as
insufficient anticoagulation, dissection, or distal emboliza-
tion leading to compromised flow and thrombosis in situ.
The association between an elevated white blood cell count
and IPST is also intriguing and deserves further study to
elucidate whether systemic inflammation plays a role in
IPST development. Recognizing the underlying cause
might allow targeted therapy to prevent IPST or to rapidly
restore antegrade perfusion if IPST occurs. However, it is
notable in our analysis that a high subsequent rate of
ischemic events (especially definite ST) occurred within 30
days of IPST, even in patients with resolution of the
thrombotic episode and restoration of normal (TIMI flow
grade 3) antegrade flow. In this regard, the present analysis
extends the findings from earlier reports in which intra-
procedural complications were associated with greater myo-
cardial necrosis but not recurrent thrombosis (19).
Although IPST was rare (0.7%), this frequency is similar
to the rate of out-of-lab ST within the first 30 days or 1 year
Whom IPST Did Versus Did Not Develop
cedural stent thrombosis (IPST) did versus did not develop. CI  conﬁdence
larization.nts in
tra-proin most large series (20). Moreover, although IPST is de
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42facto recognized and can be treated immediately in the
catheterization laboratory, its occurrence portends nearly
the same adverse prognosis in terms of early and late
mortality as out-of-lab ST. These observations are further
Figure 3. Out-of-Lab ST During 1-Year Follow-Up in Patients in Whom IPST
Out-of-laboratory deﬁnite (A) and deﬁnite or probable (B) stent thrombosis (S
Abbreviations as in Figure 2.justification as to why IPST should be considered a newclassification of ST (ARC or otherwise) and reported in all
cases.
It might be difficult to always distinguish between events
that started with thrombus and those in which new throm-
rsus Did Not Develop
ing 1-year follow-up in patients in whom IPST did versus did not develop.Did Ve
T) durbus developed, even for an expert angiographer performing
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43frame-by-frame analysis. Moreover, the angiographic core
laboratory can only evaluate events that were captured on
cine-angiography. Although investigators in the ACUITY
and HORIZONS-AMI trials were asked during site train-
ing to film all intra-procedural adverse events, we cannot
exclude the possibility that some events were not recorded
or led to misclassification or under-reporting of IPST.
Furthermore, the intensity of anticoagulation at the time of
angiographic thrombus appearance, such as minimal ACT,
is not precisely known. It is possible that the nominally
higher ACT in the IPST group reflects additional antico-
agulation given at the time of thrombus detection or from
bail-out GPI, which is known to increase ACT levels (21).
We could also not find a mechanism explaining the associ-
ation between bare-metal stent and IPST.
Conclusions
Despite these limitations, we conclude that the occurrence
of IPST is relatively rare, even in ACS patients, and is
related more strongly to clinical presentation and procedural
factors (e.g., anticoagulation regimen, lesion type, and
presence of thrombus at baseline) than to baseline demo-
graphic characteristics. The development of IPST is
strongly associated with a substantial excess of ARC-
defined out-of-lab ST in the first 30 days after PCI, which
implies that these patients might especially benefit from
more potent antiplatelet agents, such as prasugrel or ticagre-
lor. Intra-procedural ST is also a powerful independent
predictor of 1-year mortality. Therefore, IPST should be
added as a separate category to the ARC definition of ST
and be recognized as a high-risk procedural complication
portending a poor prognosis.
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